Edition:
United Kingdom

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

20.30USD
5:34pm GMT
Change (% chg)

$0.05 (+0.25%)
Prev Close
$20.25
Open
$20.40
Day's High
$20.45
Day's Low
$20.05
Volume
41,699
Avg. Vol
224,261
52-wk High
$22.25
52-wk Low
$6.00

Latest Key Developments (Source: Significant Developments)

Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Novocure Ltd ::NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA.NOVOCURE-‍JAPANESE MINISTRY OF HEALTH, LABOUR & WELFARE APPROVED RECOMMENDATION TO PROVIDE REIMBURSEMENT FOR OPTUNE TO TREAT NEWLY DIAGNOSED GLIOBLASTOMA​.  Full Article

Novocure reports qtrly ‍loss per share $0.13​
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Novocure Ltd :Novocure Ltd - Qtrly ‍loss per share $0.13​.Novocure Ltd - ‍Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016​.  Full Article

Novocure presents second cohort of phase 2 pilot panova trial results suggesting tumor treating fields
Monday, 12 Dec 2016 

Novocure Ltd : Says no serious adverse events related to ttfields were reported . Novocure Ltd- nine patients suffered from serious adverse events unrelated to ttfields therapy .Novocure presents second cohort of phase 2 pilot panova trial results suggesting tumor treating fields plus nab-paclitaxel and gemcitabine may be safe as first-line treatment and may improve one-year survival rate of patients with advanced.  Full Article

Novocure presents phase 2 pilot innovate trial results suggesting tumor treating fields plus paclitaxel may be safe as first-line treatment and may improve survival of patients with recurrent ov
Monday, 12 Dec 2016 

Novocure Ltd : Novocure - topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of ttfields in recurrent ovarian cancer .Novocure presents phase 2 pilot innovate trial results suggesting tumor treating fields plus paclitaxel may be safe as first-line treatment and may improve survival of patients with recurrent ovarian cancer.  Full Article

Novocure reports Q2 financial results
Thursday, 28 Jul 2016 

Novocure Ltd : Novocure reports second quarter 2016 financial results and provides company update . Q2 revenue $17.9 million versus I/B/E/S view $16 million .Net losses for three months ended June 30, 2016, were $40.6 million compared to net losses of $29.4 million for same period in 2015.  Full Article

Novocure receives FDA approval for second generation optune system
Wednesday, 13 Jul 2016 

Novocure Ltd : Novocure receives FDA approval for second generation optune system .Says receives FDA approval for second generation optune system.  Full Article

Novocure FDA approved investigational device exemption application to start Metis trial
Tuesday, 31 May 2016 

Novocure Ltd :Novocure Ltd says U.S. FDA has approved its investigational device exemption application to initiate Metis trial.  Full Article

Novocure enters into employment agreement with William Doyle
Wednesday, 11 May 2016 

Novocure Ltd : Novocure enters into employment agreement with William Doyle .Employment agreement with William Doyle, current chairman and director, to formally establish his role as executive chairman.  Full Article

Novocure reports Q1 loss per share $0.42
Monday, 9 May 2016 

Novocure Ltd : Novocure reports first quarter 2016 financial results and provides company update . Q1 loss per share $0.42 . Q1 revenue rose 151 percent to $13.1 million .Q1 revenue view $23.6 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma

* NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA